Table 1.
Characteristics of the 38 eligible patients with advanced gastroesophageal junction (GEJ) or gastric cancer treated with bevacizumab, docetaxel, and oxaliplatin
| Characteristic | n | % | Years |
| Age: median (range) | 57 (22–73) | ||
| Sex | |||
| Male | 29 | 76 | |
| Female | 9 | 24 | |
| Race | |||
| African American | 4 | 11 | |
| Caucasian | 32 | 84 | |
| Other | 2 | 5 | |
| Prior surgery | |||
| No | 37 | 97 | |
| Yes | 1 | 3 | |
| Performance status | |||
| 0 | 21 | 55 | |
| 1 | 17 | 45 | |
| Site of primary tumor | |||
| Stomach | 17 | 45 | |
| GEJ | 21 | 55 | |
| Stage | |||
| Locally advanced | 2 | 5 | |
| Metastatic disease | 36 | 95 | |
| Liver | 19 | 50 | |
| Lung | 14 | 37 | |
| Peritoneum | 4 | 11 | |
| Other (bone, lymph nodes) | 27 | 71 |